A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Clinical trial NCT06398444 · RECRUITING

Trial details

NCT number: NCT06398444
Sponsor: Sinotau Pharmaceutical Group
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Advanced Neuroendocrine Neoplasm

Start date: 2024-06-11
Primary completion: 2027-06-01
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.